India's Sun Pharma to buy US-listed Organon in $11.75 billion deal
India's Sun Pharma to buy US-listed Organon in $11.75 billion deal
ReutersMon, April 27, 2026 at 1:53 AM UTC
0
A bird flies past the logo of Sun Pharmaceutical Industries Ltd., outside its corporate office in Mumbai, India, October 31, 2025. REUTERS/Francis Mascarenhas
April 26 (Reuters) - Sun Pharmaceutical Industries said on Sunday it will buy Organon & Co in an all‑cash deal, valuing the U.S. drugmaker at about $11.75 billion including debt, in one of India's biggest outbound deals.
Under the agreement, Sun Pharma will buy all the outstanding shares of Organon for $14.00 per share, the companies said in a joint statement, representing a premium of more than 24% to the stock's last close on Friday.
Advertisement
With the acquisition of Organon, spun off from Merck in 2021, Sun Pharma aims to grow its innovative medicines portfolio, enter into biosimilars, and extend its push into women's health.
Sun Pharma, India's biggest pharmaceutical company with a market value of more than $40 billion, plans to fund the acquisition through a combination of available cash resources and committed financing from banks.
(Reporting by Mihika Sharma and Akanksha Khushi in Bengaluru; Editing by Subhranshu Sahu)
Source: “AOL Money”
